The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
ID Number 15-0878Principal Investigator(s)
Marla C Dubinsky
Department(s) or Division(s)
Small bowel ultrasound (SBUS) is emerging as a well tolerated, non-invasive, radiation free, low cost measure to assess inflammatory bowel disease (IBD), and is being used as first-line imaging in Europe. SBUS findings have been shown to correlate with endoscopic findings, and a small number of recent studies have looked at change in bowel wall thickness (BWT) in response to anti-TNF therapy.
The purpose of this study is to apply the use of SBUS to pediatric patients with Crohn’s disease and to assess response to treatment with infliximab. We will also measure C-reactive protein and fecal calprotectin at baseline, as well as measure IFX levels and anti-infliximab antibodies (ATI) prior to maintenance infliximab to assess change in biochemical response to infliximab treatment.
This study is novel in that it will be the first study in pediatric patients to use SBUS to assess response to IFX therapy, and will also be the first study to correlate SBUS findings with therapeutic drug monitoring (TDM).
Recruiting Patients: Yes